Tag: Ladenburg Thalmann

April 18, 2018

Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Bellicum Pharmaceuticals (NASDAQ:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited...
February 15, 2018

Catalyst Biosciences Announces Closing of Public Offering of Common Stock

Catalyst Biosciences (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced...
January 30, 2018

Auris Medical Announces Pricing of $5.5 Million Registered Direct Offering

Auris Medical (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today...
January 25, 2018

Eyenovia Announces Pricing of Initial Public Offering

Eyenovia (NASDAQ:EYEN) a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics...
January 24, 2018

UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option

UroGen Pharma (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a...
January 19, 2018

UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares

UroGen Pharma (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a...
June 16, 2017

Friday Night Inc, formerly QuikFlo Health Inc. announces name change, share consolidation, closing of acquisition of Las Vegas medical marijuana interests, private placement closing and management changes

Friday Night Inc, formerly QuikFlo Health Inc. (the “Company“) (CSE:TGIF) (FRANKFURT:1QF) announces that in conjunction with the closing of its...